Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of MEDI-573 in Japanese subjects with advanced solid tumours
jRCT2080221544Phase 1
- Sponsor
- AstraZeneca
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dusigitumab in Solid tumor, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of MEDI-573 and Pharmacokinetics of MEDI-573.
02
Drugs
dusigitumab
03
Conditions
Solid tumor
Beyond the preview
Go deeper on jRCT2080221544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221544.